Is GENERAL PHYSICAL HEALTH DETERIORATION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

Study of possible correlation between GENERAL PHYSICAL HEALTH DETERIORATION and SORAFENIB (RAF KINASE INHIBITOR)

Accompanying discussion about FactMed users Questions and Concerns

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed GENERAL PHYSICAL HEALTH DETERIORATION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 64 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported GENERAL PHYSICAL HEALTH DETERIORATION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and GENERAL PHYSICAL HEALTH DETERIORATION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause GENERAL PHYSICAL HEALTH DETERIORATION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes GENERAL PHYSICAL HEALTH DETERIORATION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if GENERAL PHYSICAL HEALTH DETERIORATION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing GENERAL PHYSICAL HEALTH DETERIORATION: 64
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where GENERAL PHYSICAL HEALTH DETERIORATION is a reported side effect: 1.9225%

FDA reports of any drug causing GENERAL PHYSICAL HEALTH DETERIORATION : 32389
Average percentage for all medicated patients where GENERAL PHYSICAL HEALTH DETERIORATION is reported as a complication: 0.2030%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with GENERAL PHYSICAL HEALTH DETERIORATION:

ZOMETA (3877 patients)
YAZ (2956 patients)
YASMIN (2798 patients)
ASPIRIN (2358 patients)
MAGNEVIST (2354 patients)
AREDIA (1658 patients)
OMNISCAN (1481 patients)
PREDNISONE (1433 patients)
LASIX (1360 patients)
FUROSEMIDE (1323 patients)
OMEPRAZOLE (1274 patients)
DEXAMETHASONE (1268 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (1222 patients)
NEXIUM (1174 patients)
ACETAMINOPHEN (1161 patients)
PREDNISOLONE (1081 patients)
OPTIMARK (994 patients)
METHOTREXATE (926 patients)
LISINOPRIL (900 patients)
HUMIRA (888 patients)
NEURONTIN (872 patients)
SIMVASTATIN (872 patients)
COUMADIN (872 patients)
ALLOPURINOL (866 patients)
LIPITOR (863 patients)
OXYCONTIN (846 patients)
IBUPROFEN (837 patients)
LEVOTHYROXINE SODIUM (837 patients)
PROHANCE (819 patients)
MULTIHANCE (815 patients)
LORAZEPAM (815 patients)
CISPLATIN (759 patients)
FOLIC ACID (753 patients)
FLUOROURACIL (734 patients)
PRILOSEC (728 patients)
DIGOXIN (719 patients)
CYCLOPHOSPHAMIDE (712 patients)
AMBIEN (702 patients)
ATENOLOL (694 patients)
PLAVIX (694 patients)
REVLIMID (677 patients)
LYRICA (675 patients)
POTASSIUM CHLORIDE (675 patients)
MORPHINE (674 patients)
ZOLOFT (655 patients)
ATIVAN (655 patients)
PROTONIX (645 patients)
PERCOCET (643 patients)
XANAX (634 patients)
VELCADE (620 patients)
AMOXICILLIN (612 patients)
ZOFRAN (608 patients)
AVASTIN (602 patients)
DECADRON (593 patients)
FORTEO (590 patients)
PREDNISONE TAB (589 patients)
RAMIPRIL (588 patients)
ALBUTEROL (587 patients)
OXYCODONE HCL (583 patients)
EFFEXOR (573 patients)
SYNTHROID (571 patients)
XELODA (571 patients)
VICODIN (571 patients)
GABAPENTIN (559 patients)
NORVASC (549 patients)
MORPHINE SULFATE (543 patients)
METFORMIN HCL (543 patients)
TAXOTERE (534 patients)
WARFARIN SODIUM (530 patients)
CELEBREX (529 patients)
METOPROLOL TARTRATE (528 patients)
CAPECITABINE (527 patients)
HEPARIN SODIUM INJECTION (524 patients)
SPIRONOLACTONE (515 patients)
CIPROFLOXACIN (505 patients)
VIOXX (502 patients)
CLOZARIL (499 patients)
FENTANYL (498 patients)
HYDROCHLOROTHIAZIDE (494 patients)
CHEMOTHERAPEUTICS NOS (491 patients)
VANCOMYCIN (490 patients)
ARANESP (489 patients)
TYSABRI (488 patients)
DURAGESIC-100 (477 patients)
EPOGEN (475 patients)
CARBOPLATIN (475 patients)
TOPROL-XL (468 patients)
ZOCOR (464 patients)
ZYPREXA (458 patients)
AMLODIPINE (451 patients)
FOSAMAX (447 patients)
FEMARA (444 patients)
COMPAZINE (438 patients)
LEVAQUIN (438 patients)
VITAMIN D (438 patients)
PANTOPRAZOLE (427 patients)
TRAMADOL HCL (425 patients)
LEXAPRO (420 patients)
LANTUS (417 patients)
CALCIUM (412 patients)
GADOLINIUM IN UNSPECIFIED DRUG (411 patients)
SEROQUEL (411 patients)
PREVACID (406 patients)
BACTRIM (406 patients)
INSULIN (405 patients)
SANDOSTATIN LAR (402 patients)
DIOVAN (401 patients)
BISOPROLOL FUMARATE (401 patients)
OXALIPLATIN (397 patients)
THALIDOMIDE (395 patients)
BEVACIZUMAB (387 patients)
FLUCONAZOLE (384 patients)
ADVAIR DISKUS 100/50 (382 patients)
REMICADE (382 patients)
PANTOPRAZOLE SODIUM (378 patients)
VINCRISTINE (378 patients)
HEPARIN (378 patients)
MULTI-VITAMINS (373 patients)
LOVENOX (369 patients)
LORTAB (369 patients)
PACLITAXEL (368 patients)
TAXOL (366 patients)
GLEEVEC (366 patients)
METOCLOPRAMIDE (366 patients)
VITAMIN B-12 (365 patients)
RENAGEL (364 patients)
LANSOPRAZOLE (364 patients)
SORAFENIB (361 patients)
ALDACTONE (360 patients)
ACYCLOVIR (356 patients)
AUGMENTIN '125' (354 patients)
RADIATION THERAPY (352 patients)
PAXIL (350 patients)
GEMZAR (350 patients)
ALPRAZOLAM (348 patients)
FERROUS SULFATE TAB (347 patients)
LACTULOSE (347 patients)
RISPERDAL (345 patients)
TAMOXIFEN CITRATE (345 patients)
CYMBALTA (338 patients)
SPIRIVA (338 patients)
COREG (335 patients)
DOXORUBICIN HCL (335 patients)
PROGRAF (333 patients)
CITALOPRAM HYDROBROMIDE (332 patients)
DILAUDID (332 patients)
CLONAZEPAM (332 patients)
NITROGLYCERIN (329 patients)
CALCIUM CARBONATE (329 patients)
RITUXIMAB (327 patients)
ENALAPRIL MALEATE (326 patients)
REGLAN (322 patients)
SUTENT (314 patients)
METRONIDAZOLE (312 patients)
DOCETAXEL (311 patients)
SOLU-MEDROL (310 patients)
TORSEMIDE (309 patients)
METHYLPREDNISOLONE (307 patients)
CLINDAMYCIN (305 patients)
MS CONTIN (304 patients)
WELLBUTRIN (303 patients)
EXJADE (299 patients)
HALDOL (298 patients)
CELEXA (298 patients)
MOTRIN (295 patients)
CLOZAPINE (295 patients)
FASLODEX (293 patients)
KEPPRA (292 patients)
AFINITOR (290 patients)
DIAZEPAM (290 patients)
MIRTAZAPINE (288 patients)
CYTARABINE (288 patients)
AVONEX (287 patients)
CLONIDINE (285 patients)
CRESTOR (281 patients)
ALTACE (278 patients)
ARIMIDEX (275 patients)
EXELON (274 patients)
CORDARONE (274 patients)
GLUCOPHAGE (273 patients)
DIFLUCAN (273 patients)
ENBREL (273 patients)
ZITHROMAX (271 patients)
DEXAMETHASONE TAB (270 patients)
AMITRIPTYLINE HCL (268 patients)
ROCEPHIN (266 patients)
CELLCEPT (265 patients)
HYDROCORTISONE (264 patients)
NEUPOGEN (263 patients)
LOPRESSOR (257 patients)
METOPROLOL SUCCINATE (256 patients)
AVANDIA (255 patients)
CYCLOSPORINE (255 patients)
KALETRA (254 patients)
TEMAZEPAM (254 patients)
RANITIDINE (252 patients)
ZANTAC (251 patients)
AZITHROMYCIN (251 patients)
PERIDEX (250 patients)
FLEXERIL (250 patients)
ZYRTEC (248 patients)
FAMOTIDINE (245 patients)
ZOLPIDEM (245 patients)
FLAGYL (244 patients)
PROZAC (243 patients)
ONDANSETRON (242 patients)
AMIODARONE HCL (240 patients)
KLONOPIN (238 patients)
ENOXAPARIN SODIUM (238 patients)
TRAZODONE HCL (237 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about GENERAL PHYSICAL HEALTH DETERIORATION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.